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Summary: Cisplatin, a nephrotoxic chemotherapeutic agent, was injected into Sprague Dawley rats, alone or
together with cysteine, vitamin E and clonidine. The effects on erythrocyte fragility, serum composition, and kidney
and liver enzymes were studied.
Cisplatin was administered äs two i. p. injections (6 mg/kg body weight) at an interval of 120 hours. The animals
were sacrificed 24 hours after the second injection. Erythrocytes were prepared from blood collection with anticoag-
ulant. Serum was prepared from clotted blood, collected without anticoagulant. Kidneys and liver were removed
and homogenized, and a supernatant prepared by high speed centrifugation.
In cisplatin-treated rats, the serum activities of aspartate aminotransferase, alanine aminotransferase, lactic dehydro-
genase and alkaline phosphatase were significantly decreased, whereas the activities of isocitric dehydrogenase and
glutathione reductäse were increased. Also, concentrations of blood urea nitrogen, creatinine, total lipids and magne-
sium increased while albumin and glucose decreased.
Mean osmotic fragility of erythrocytes from cisplatin-treated rats was decreased, while the haematocrit was
increased.
In the liver, the only change seen was an increased activity of isocitric dehydrogenase. Much greater changes were
found in the kidneys, with increased activity of glucose-6-phosphate dehydrogenase and decreased activities of
aspartate and alanine aminotransferäses, alkaline phosphatase, malic dehydrogenase, sorbitol dehydrogenase and -
glütamyltransferase, äs well äs a decreased phosphorylation to oxidation ratio in the mitochondria, indicating re-
duced adenosine triphosphate production.
Administration of cysteiiie and Vitamin E together with cisplatin partially reversed the uraemia and many of the
biochemical changes induced by cisplatin.
The observed intra- and extracellular biochemical changes indicate a basis for the toxic effects of cisplatin, and
suggest a possible way of coünteracting the toxicity by introducing protective agents such sulphydryl compounds
and pther antioxidants. It also appears that cells adapt to the effects of cisplatin through the induction of Systems
that produce NADPH, whieh in turn compeusates the decrease of free sulphydtyl groups.
Introduction istration of this drug however results in a significarit
. _ _ . · · · · impairment of renal function (6—10).
czs-Diammme dichloroplatmiim (cisplatin) is an impor-
tant chemotherapeutic agent used effectively in the treat- Foilowing the administration of cisplatin to rats, both
ment of cancers of the testes, ovary, head and neck, the inulin clearance rate and the glomerular filtration
bladder, prostate and other organs <l-5). The admin- rate afe reduced (6-l6).
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Tab. l Enzyme catalytic concentrations in sera of conlrol and cisplatin-treated rats
Control
Cisplatin
Aspartate
amino-
transferase
(U/l)
169 ±8
141 ±5*
Alanine
amino-
transferase
(U/l)
51 ±3
40 ±2*
Isocitrate
dehydro-
genase
(U/l)
9± 1
12± 1*
Lactate
dehydro-
genase
(U/l)
3250 ± 110
2889 ± 108*
Malic
enzyme
(U/l)
50 ±5
56 ±7
Glutathione
reductase
(U/l)
52 ± 1
78 t 5*
Alkali ne
phospha-
tase
(U/l)
383 ± 13
f
 201 ± 13*
Malate
dehydro-
genase
(U/l)
1296 ± 33
1124 ±63
χ ± sem, n = 17-39
* significantly different (p < 0.01)
Tab. 2 Metabolites and protein concentrations in the sera of control and cisplatin-treated rats
Control
Cisplatin
Blood
urea
nitrogen
(mmol/1)
8.2 ± 0.3
69 ±5*
Creatinine
(μιηοΐ/ΐ)
75 ± 6
380 ± 35*
Glucose
(mmol/1)
7.6 ± 0.2
6.7 ± 0.4*
Total-
proteins
(g/0
64 ± 1
59 ±2
Albumin
(g/0
30 ± 1
27 ± 1*
Globulins
(g/l)
34 ± 1
32 ±2
Albumin/
globulin
ratio
0.88
0.84
Total
lipids
(g/0
4.9 ± 0.2
5.8 ± 0.3*
Total
lipids/
glucose
ratio
(g/mrnol)
0.64
0.87
χ ± sem; n = 17—39
* significantly difFerent (p < 0.01)
Biochemical studies with heavy metals show that they
react with free sulphydryl groups. It is postulated that
the nephrotoxicity caused by several heavy metals, e. g.
mercury, is related to the intracellular decrease of re-
duced glutathione; enzymes are then inactivated because
their SH-groups are not maintained in a reduced form
(12). Levi et al. (15) showed that following the admin-
istration of cisplatin to rats, there was a significant
decrease of SH groups per gram wet weight. This
change was seen prior to the elevation of blood urea
nitrogen and creatinine in the blood, suggesting that SH
group depletion may be a primary event leading to the
renal failure. The decrease of SH groups was due to a
decrease of protein-bound SH, with the greatest decline
in the cytosolic and mitochrondrial fractions (15).
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Fig. l Mean relative activity of enzymes in cisplatin-treated rat"
sera.
Ways of protecting SH groups and reducing the toxic
effects caused by cisplatin have been repprted (17-19).
The objectives of this study were to obtain Information
on the effects of cisplatin on various enzyme Systems in
the kidney, liver and blood, to relate these effects to
renal failure, and to evajuate possible methods of revers-
ing these effects by a administering compounds that pro-
tect or increase SH groups.
Materials and Methods
White male, 60 days old Sprague-Dawley rats, weighing 260 ± 10
grams were used. Cisplatin was injected i. p. (6 mg/kg body
weight) twice, the second injection, being given 120 hours after
the first. The animals were sacrificed 24 hours after the second
injection. Blood was taken from the abdominal aorta for the prep -
ration of serum. Haematocrit and erythrocytes mean osmotic fragil-
ity were determined on heparinized blood.
Immediately after compiete bleeding and death of the animal, tis-
sues were taken, cooled to 0—4 °C and hornogenized; a cell-free
supernatant was prepared for the determination of enzyme levels.
Homogenization and fractionation were done according ' to a
method previously described by Bogin et al. (20). Three fractions
were obtained: mitochondria, rnicrosomes and soluble fraction.
Liver and kidney tissues were homogenized in 10-fold volumes of
sucrose (0.25 mol/1, tris buffer 0.02 mol/1, pH 7.4) with a teflon-
glass homogenizer. Prior to homogenization, the tissues were cut
into small pieces and washed three times with fche homogenizing
solution. The homogenate was first centrifiiged at 3000g for 15
minutes to remove connective tissue, cell debris, nuclei and mem-
branes. The supernatant obtained was recentrifuged at 18 000 g for
30 minutes. The sediment was washed (Suspension and recentrifu-
gation in the homogenizing solution) then used s the mito-
chondrial fraction. The supernatant was recentrifuged at 100000g
for 60 minutes, and the resulting sediment used s the microsomal
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Tab. 3 Electrolyte concentrations in the sera of control and cis-
platin-treated rats
Control
Cisplatin
Calcium
(mmol/1)
2.84 ± 0.05
2.89 ± 0.07
Magnesium
(mmol/1)
0.99 ± 0.04
1.44 ±0.08*
Inorganic
phosphorus
(mmol/I)
3.10 ±0.13
3.33 ±0.19
± sem; n = 13-23
* significantly different (p < 0.01)
Tab. 4 Haematocrit and mean osmotic fragility of erythrocytes
from control and cisplatin-treated rats
Haematocrit Mean osmotic
fragility
(g/l NaCl)
Control
Cisplatin
0.417 ± 0.007
0.461 ±0.009*
3.91 ± 0.02
3.72 ± 0.02*
± sem; n = 8-12
* significantly different (p < 0.01)
fraction. This final supematant was used for the determination of
soluble enzymes.
Blood was allowed to clot, serum was obtained and the following
enzymes were assayed: L-aspartate 2-oxoglutarate aminotransfer-
ase, EC 2.6.1.1 (21), L-alanine 2-oxoglutarate aminotransferase,
EC 2.6.1.2 (22), L-malate : NAD oxidoreductase, EC 1.1.1.37 (23),
,-isocitrate : NADP oxidoreductase, decarboxylating, EC l. l. 1.42
(24), I-lactate : NAD oxidoreductase, EC 1.1.1.27 (25), L-malate
: NADP oxidoreductase, oxaloacetate decarboxylating, EC l. l. l .40
(malic enzyme) (26), NAD(P)H : oxidized glutathione oxidoreduc-
tase, EC 1.6.4.2 (27), orthophosphoric rnonoester phosphobydro-
lase, EC3.1.3.1 (28).
In the supematant obtained from the homogenized tissues, addi-
tional enzymes were assayed: L-iditol: NAD 5-oxidoreductase, EC
1.i. 1.14 (29), D-glucose-6-phosphate dehydrogenase, EC 1.1.1.49
(30), ,- -glutamyltransferase, EC 2.3.2.2 (31).
The enzymes, Na^K^-adenosine triphosphatase, EC 3.6.1.3
(Na+,K"l"-ATPase), and Mg-adenosine triphosphatase, EC 3.6.1.4
(Mg^-ATPase), were assayed according to Post & Sen (33) in
the microsomal fractions obtained frorn the homogenized tissues.
Mütochondriäl fraction was prepared according to Johnson & Lardy
(33). Mitochondrial oxidative phosphorylation was measured with
a Gilson respirometer at 30 °C according to Smith (34). Free sul-
phydryl groups were measured in the supematant according to Sed-
lak&Lindsäy (35). Protein in the various fractions was determined
according to Lowry et ail. (36), and the activities were expressed
per g protein.
The following constituents were measured in the serum: blood urca
nitrogen - enzymaticaUy (37); creatinine - colorimetrically (38);
älbumin — colorimetrically (39); total protein — colorimetrically
(40); glu'cose - enzyrnatically (41); total lipids - colorimetrically
(42); caicium (43) and magnesium (44) — colorimetrically; and
inorganic phosphorus - colorimetrically (45). Mean osmolic fra-
gility of the erythrocytes was measured on freshly withdrawn cells
according to Parpart (46).
Internal (high and low levels) and external (DADE) quality control
programs were used.
Trials to reduce the nephrotic effects of cisplatin were performed.
The substances evaluated were:
1) cysteinc — a SH-containing amino acid with the potential to
protect endogenous SH-groups, and, therefore to reduce the dam-
age causcd by cisplatin;
2) vitamin E, a substance known for its antioxidative activity and
thus a potential agent for protection of SH-groups. Cysteine and
vitamin E were used together to determine whether the combina-
tion of the two offers greater protection;
3) clonidine, a substance used äs a detoxirying agent in cases of
heavy metal poisoning (15). The effects of clonidine and cysteine
+ vitamin E were studied in the absence and in the presence of
cisplatin. Clonidine was given in the drinking water (4.5 mg/1
waler). Cysteine (20 mg/kg body weight) was injected together
with cisplatin. Vitamin E (2 mg/rat) was dissolved in corn oil
l : 50, and injected s. c. together with cisplatin and cysteine.
Student's t-test was used for statistical analysis of the result.
Results
There were small but significant changes in most serum
enzymes studied. While isocitric dehydrogenase and
glutathione reductase activities were significantly
(p < 0.01) higher in cisplatin-treated rats, the levels of
aspartate aminotransferase, alanine aminotransferase,
lactic dehydrogenase and alkaline phosphatase were sig-
nificantly lower. No significant differences were seen in
the level of malic dehydrogenase and malic enzyme (tab.
l and fig. 1).
The concentrations of serum proteins and metabolites in
control and cisplatin-treated rats are given in table 2.
There were large significant increases in blood urea ni-
trogen (406%) and creatinine (740%) indicating renal
function insufficiency. Small but significantly
(p < 0.01) lower concentrations of blood glucose and
serum älbumin and higher total lipids were seen in the
sera of cisplatin-treated rats.
Tab. 5 Enzyme catalytic concentrations in liver of control and cisplatin-treated rats
Control
Cisplatin
Aspartate
aminp-
transferase
(U/g protein)
700 ± 42
822 ± 83
Alanine
amino-
transferase
(U/g protein)
507 ± 40
575 ± 69
Sorbitol
dehydro-
genase
(U/g protein)
134 ±7
129 ±7
Malaie
dehydro-
genase
(U/g protein)
4208 ± 151
4010 ±250
Lactate
dehydro-
genase
(U/g protein)
3520 ± 569
3292 ± 381
Isocitrate
dehydro-
genase
(U/g protein)
66 ±4
9l ±9*
Alkaline
phosphatase
(U/g protein)
15.7 ± 0.7
16.7 ± 1.8
x ± sem; n = 9
* significantly different (p < 0.01)
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While serum magnesium was significantly (p < 0.01)
higher (4-45%) in the cisplatin-treated rats, serum
calcium and inorganic phosphorus did not change
(tab. 3).
The effects of cisplatin on the erythrocytes are shown in
table 4. There was a significant (p < 0.01) increase
(10%) in the haematocrit and a decrease (5%) in the
mean osmotic fragility.
Analysis of the soluble enzyme fraction from liver
showed a significant mean increase of 38% (p < 0.01)
in the activity of NADP-isocitric dehydrogenase from
the cisplatin-treated rats, compared with the controls.
There were no significant changes in the other enzymes
studied (tab. 5). Levels of soluble enzymes in the kid-
neys of control and cisplatin-treated rats are shown in
table 6 and figure 2. A mixed pattern was seen. Aspar-
tate aminotransferase, alanine aminotransferase, alkaline
phosphatase, malic dehydrogenase, sorbitol dehydroge-
nase and γ-glutamyltransferase showed significantly
(p < 0.01). lower specific actiyities, while glucose 6-
phosphate dehydrogenase was significantly higher in the
cisplatin-treated rats. No significant changes were seen
in the activities of isocitric dehydrogenase, lactic dehy-
drogenase, malic enzyme and glutathione reduct se.
Measurement of mitochondrial oxidation and phosphor-
ylation showed that the P/O ratio was decreased in mito-
chondria from the kidneys of cisplatin-treated rats, i. e.
these mitochondria were less efficient in the production
of adenosine triphosphate. While oxidation levels were
almost identical in both groups, phosphorylation was
significantly (p < 0.01) lower in the cisplatin-treated
group, decreasing the P/O ratio by 15% (tab. 7).
The effects of clonidine, cysteine and vitamin E on
changes induced by cisplatin in serum enzymes are
300
control
l
·
l
l
Fig. 2 Mean· relative activity of enzymes in cisplathvtreated rat
kidney.
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Tab. 7 Mitochondrial oxidation and phosphorylation from kidney
of control and cisplatin-treated rats
Control
Cisplatin
Oxygen
consumption
('/2θ2, μητιοί/
h · mg protein)
10.9 ± 0.5
10.7 ± 0.7
Phosphorylation
(μιηοΐ/
h · mg protein)
17.8 ±0.7
15.1 ±0.6*
P/0
quotient
1.64 ±0.10
1.42 ±0.04*
succinate was used s a Substrate
* significantly different (p < 0.01)
n = 7-10
given in table 8. While serum aspartate aminotransferase
was significantly lower after administration of cisplatin
alone, the activity was not significantly different from
the control when cisplatin was administered together
with clonidine or together with cysteine and vitamin E.
Addition of clonidine alone did not significantly change
serum aspartate aminotransferase activity. Administra-
tion of cysteine and vitamin E alone significantly
increased serum aspartate aminotransferase activity by
about 22%. This Stimulation however was abolished
whenever cisplatin was injected together with cysteine
and vitamin E. Cisplatin significantly lowered the activ-
ity of alanine aminotransferase, whereas clonidine, or
cysteine together with vitamin E, given without cisplatin
did not affect serum enzyme activity. Clonidine together
with cisplatin did not reverse the lowered activity of
the enzyme. Cysteine and vitamin E given together with
cisplatin led to an even greater decrease than that seen
with cisplatin alone. Cisplatin caused a reduction in the
activity of serum lactic dehydrogenase. While clonidine
caused a significantly higher activity, cisplatin adminis-
tered together with clonidine caused an even greater
decrease of serum lactic dehydrogenase (tab. 8). Cyste-
ine + vitamin E administered alone, or cisplatin to-
gether with cysteine + vitamine E caused no effect on
serum malic dehydrogenase activity. Clonidine on the
other band led to increased activity of malic dehydroge-
nase. Cisplatin administered together with cysteine and
vitamin E caused a significant decrease of serum malic
dehydrogenase.
Cisplatin, clonidine and cysteine + vitamin E, alone or
in combination, led to lower serum alkaline phosphatase
activity. Clonidine, cysteine and vitamin E did not re-
verse the inhibitory effect on alkaline phosphatase by
cisplatin (tab. 8).
Cisplatin and clonidine led to increased activity of gluta-
thione reductase when added together, and the Stimula-
tion was additive. Cysteine and vitamin E, added alone
or together with cisplatin, caused little or no effect on
the serum activity of glutathione reductase (tab. 8).
The effects of cisplatin, clonidine, cysteine and vitamin
E on kidney enzymes are shown in table 9. Alanine ami-
notransferase from kidney was lower following cisplatin
treatment, while higher activity was seen following
treatment with clonidine. Whenever both cisplatin and
clonidine were administered together, the effects of each
drug were neutralized by the other, so that the activity
was similar to that of the untreated control group. Kid-
ney sorbitol dehydrogenase activity was lowered by
clonidine and cisplatin, and a cumulative Inhibition was
seen whenever both drugs were administered together.
Cysteine and vitamin E caused a similar Inhibition to
that of cisplatin, but no additive effect was seen (about
A large Stimulation of kidney glucose-6-phosphate de-
hydrogenase was seen following the administration of
cisplatin. No significant effects of clonidine, cysteine
Tab. 8 Enzyme catalytic concentrations in the sera of rats following injection of cisplatin, clonidine,
cysteine and vitamin E
Control
Cisplatin
Clonidine
Cysteine 4-
vitamin E
Cisplatin +
clonidine
Cisplatin +
cysteine +
vitamin E
Aspartate
aminor
transfer se
(U/l)
169 ± 8
141 * 5a
Ί59 ± 14
206 ± 18a-b
159 ± 14
162 it 11
Alanine
amino-
transferase
(U/l)
51 ±3
40±2a
56 ± 5b
46 ±6
45 ±6
32 ± 2a»b
Lactate
dehydro-
genase
(U/1)
3250 ± 110
2889 ± 108a
4963 ± 560a*b
3058 ± 218
2551 ±215a-b
2562 ± 246a-b
Malate
dehydro-
genase
(U/l)
1296 ± 77
1124 ± 63
1577 ± 74a-b
1235 ± 159
1107 ±212
938 ± 148a-b
Alkaline
phosphatase
(U/l)
383 ± 13
201 ± 13a
290 ± 32a-b
305 ± 23a-b
182 ± 18a
205 ± 25a
Glutathione
reductase
(U/l)
52 ± 1
78±5 a
70 ± 3a
54±6 b
110±7a-b
57±7b
Isocitrate
dehydro-
genase
(U/l)
9± 1
12 ± la
—
11 ±2
—
13 ±2a
x ± sem;n =s 11-36
a - significantly different, p < 0.01, from control
b - significantly diiferent, p < 0.01, from cisplatin-treated
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and vitamin E, added alone or together with cisplatin,
were seen (tab. 9). While kidney Mg2+-adenosine tri-
phosphatase was significantly lower following cisplatin
treatment and higher following clonidine treatment, no
significant effect was seen in the activity of Na+,KH~-
adenosine triphosphatase. TPjie Inhibition of kidney
Mg2"h-adenosine triphosphatase was reversed by the ad-
dition of clonidine (tab. 9).
The effects of cisplatin, clonidine, cysteine and vitamin
E on serum proteins, metabolites and electrolytes are
giveii in table 10. Blood urea nitrogen and creatinine
increased from rriean values of 8.2 ± 0.3 inmol/1 and
75 ± 6 μιηοΐ/ΐ respectively, to 69 ± 5 mmol/I and 380
±35 μπιοΐ/ΐ respectively. While clonidine alone had
little to no effect on the levels of these metabolites, it
significantly increased renal failure when administered
together with cisplatin. On the other hand, cysteine and
vitamin E significantly reverse some of the effects pf
renal failure caused by cisplatin (tab. 10). Administra-
tion of cisplatin led to an increase in the serum concen-
tration of Mg pf almpst 50% (p < 0.01). This effect was
partially reversed by cysteine and vitamin E but not by
clonidine (tab. 10).
Discussion
The present investigatipn focused on the biochemical s- J1
pects, kinetics and mode of action of toxic effects caused
by cisplatin.
The serum enzymes, aspartate aminotransferase, alanine
aminotransferase, lactic "defrydrogenase and alkaline
phosphatase, s well s others, are commonly elevated
following cellular damage s a result of enzymes leak-
age from cells to the blood. The serum catalytic coneen-
trations of these enzymes however were significantly
lower 120 hours post cisplatin administration in the
treated anim ls, suggesting an inhibitory effect. Lower
enzyme levels may be due tp either lower release from
the tissues to the serum, or decreased production of
active enzymes and consequently lower activity in the
serum.
It has been postulated that the nephrotoxic mode of ae-
tion of the drug cisplatin is similar to that of other heavy
metals, and is related to the decrease in the intracellular
concentrations of glutathione and protein-bpund SH-
groups, which are required for normal celMar function ··?·
(1^5,8-11,14,15).
The possibility that cisplatin itself is the inhibitory agent l
of the enzymatic reaction was excluded by the fact thatΊ»ι
in vitro addition of the drug to the reactioii media did !
not affect the reaction rates .(unpublished bservations).
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Tab. 10 Protein, melabolite and electrolyte concentrations in the sera of rats following injection of
cisplatin, clonidine, cysteine and vitamin E
Control
Cisplatin
Clonidine
Cysteine +
vitamin E
Cisplatin +
Clonidine
Cisplatin +
cysteine +
vitamin E
Blood urea
nilrogen
(mmol/1)
8.2 ± 03
69.0 ± 5.0a
8.5 ± 0.7
7.0 ± 0.7
83 ± 5a-b
50 ±9a
Creatinine
(μηιοΐ/ΐ)
75 ±
380 ±
57 ±
80 ±
610 ±
168 ±
6
35a
4
6
80a-b
27a,b
Total
proteins
(g/l)
64 ± 1
59 ±2
67 ± 2b
65 ±2
60 ±2
60 ±2
Albumin
(gfl)
30 ± 0,4
27 ± 0.6°
35 ± 1.5b
30 ± 0.8
27 ± 1 .5
29 ± 0.6
Total
lipids
(mmol/1)
4.9 ± 0.2
5.8 ± 0.3°
4.9 ± 0.2
4.8 ± 0.4
5.6 ± 0.3
5.2 ± 0.5
Glucose
(mmol/l)
7.6 ± 0.2
6.7 ± 0.4a
6.9 ± 0.3
6.8 ± 0.4
6.6 ± 0.3a
6.2 ± 0.4a
Ca
(mmol/1)
2.84 ± 0.05
2.89 ± 0.07
2.82 ±0.10
2.79 ±0.10
2.71 ± 0.24
2.74 ± 0.08
Mg
(mmol/1)
0.99
1.44
0.99
1.09
1.56
1.28
±0.04
± 0.08a
±0.04
±0.07
± 0.08a
± 0.05a
P
(mmol/l)
3. 10 ±0.13
3.33 ±0.19
2.87 ±0.13
3.52 ± 0.36
3.33 ± 1.03
2.84 ± 0.26
χ ± sem; n = 11 —36
a — significantly different, p < 0.01, from control
b — significantly different, p < 0.01, from cisplatin-treated
The lower activities of enzymes in the serum parallelled
the intracellular pattern. Administration of substances
containing sulphydryl groups, or with antioxidant prop-
erties, together with cisplatin, significantly reversed the
inhibitory effects caused by cisplatin alone, supporting
the hypothesis that the cisplatin toxicity is associated
with the reduction of free sulphydryl groups.
Addition of both cysteine and vitamin E significantly
reversed the toxic effects caused by cisplatin. The degree
of uraemia was lowered and the magnitude of the
changes in the serum analytes, including glutathione re-
ductase, were smaller. These findings may suggest that
some of the toxic effects caused by cisplatin may be
reduced by u$ing cysteine and vitamin E. This, however,
needs to be further studied, in case the chemotherapeutic
eifect of cisplatin is also reduced.
In response to the lower SH concentrations caused by
cisplatin, we observed:
(a) increased activities of the serum enzymes, NADP-
isocitric dehydrogenase and glutathione reductase,
(b) significant increases in liver isocitric dehydrogenase
and kidney glucose ^phosphate dehydrogenase, all of
these enzymes being associated with NADPH genera-
tion and maintenance of reduced sulphydryl groups.
Tab. 11 Effect of time of second cisplatin injection on renal func-
tion
Time
(h)
0
72
96
120
Blood urea riitrogen
(mmol/1)
9± 1
75 ± 14
62 ± 9
70 ± 9
Creatinine
(μτηοΐ/ΐ)
80 ± 9
398 ± 115
362 ± 62
354 ± 71
x ± SD; n = 11-36
By constantly preventing oxidative processes, sulphy-
dryl groups also have an important role in the mainte-
nance of cellular membrane integrity. The lowering of
the SH level caused by cisplatin could be a contributing
factor to the observed decrease in mean osmotic fragil-
ity.
The effect of cisplatin was much greater on the kidney
than the liver. While only one enzyme was found to
change in the liver (NADP isocitric dehydrogenase,
increasing by 38%), seven kidney enzymes showed a
change in activity (six reduced and one increased). Re-
nal failure in rats treated with cisplatin could be a result
of the lower enzymatic activities in the kidney, s well
s the less efficient oxidative phosphorylation and aden-
osine triphosphate production of the mitochondria. The
enzyme shown to be most inhibited both in the serum
and kidney is alkaline phosphatase. The reason for its
great sensitivity is not clear. Through its role s a mem-
brane enzyme involved in transmembranal transport
(arnong other functions), alkaline phosphatase may be
particularly involved in the renal failure and develop-
ment of uraemia.
Following the administration of cisplatin, uraemia devel-
oped and the activity of serum enzymes was signifi-
cantly decreased (tab. 11). This was largely reversed by
supplementation with cysteine and vitamin E (but not
clonidine), once again indicating on the possible poten-
tial of these compounds to reverse the toxic effects
caused by cisplatin. Similar patterns, although of lesser
magnitude, were also seen with other kidney enzymes
(alanine aminotransferase and aspartate aminotransfer-
ase). It is, however, necessary to evaluate the efficiency
of these compounds when given after cisplatin treatment
rather than during treatment, since the combined supple-
mentation of cisplatin together with vitamin E and cyste-
ine may reduce the chemotherapeutic efficiency of cis-
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platin. The availability of appropriate biochemical indi-
cators of the degree of nephrotoxicity will enable further
study of these aspects of the problem,
Of interest is the effect of clonidine, which did not re-
verse the toxic effects of cisplatin, but in most cases
even increased the toxicity of the chemotherapeutic sub-
stance.
The increased blood cell volume seen in the cisplatin-
treated rats could be related to the renal failure, leading
to loss of body fluids and haemoconcentration and there-
fore an increased haematocrit. The fact that total protein
was reduced could be explained by the loss of protein
in the urine. Significant proteinuria was seen in the cis-
platin-treated rats, confirming the results of other others
(9). This is further supported by the lower serum albu-
min levels in the treated rats.
Evaluation of the toxicological effects of cisplatin leads
to the following conclusions.
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